PharmiWeb.com - Global Pharma News & Resources
25-Jun-2019

Tuberculosis Drugs Market Share will Increase USD 1,432 Million by 2024 ,Internationally| Progressing CAGR 4.6%

The Global Tuberculosis Drugs Market is expected to grow progressive from USD 1,046 million in 2017 to USD 1,432 million in 2024 at a progressing CAGR of 4.6% during the forecast period.

The Global Tuberculosis Drugs Market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period of 2018 to 2024. The report offers of historic and future market scenario in terms of market value, share and critical developments taking place in the industry. Market size, forecast, trends of each country and region are studied in the report for the focus period of 2018 to 2024.

We can provide sample pages for a better understanding of this report.
Request Sample of This Report @ http://www.amecoresearch.com/sample/12314

Qualitative assessment tools such as PEST analysis, cost structure analysis and regulatory compliance for pharmaceutical products are offered in the report. The report also comprises Pipeline Analysis which helps understand the comprehensive forecast scenario of the market in terms of value and dynamics. The report analyses the recent drug approval trends and market dynamics such as drivers, restrains, and opportunities, industry trends and future outlook in the Global Tuberculosis Drugs Market.

The report represents key players operating in the market along with its competitive landscape. The competitive landscape includes player positioning analysis, competitive matrix and market share analysis of the key players operating in the industry. The market attractive index highlights the most lucrative regional market to invest in the market.

The market is studied for regions such as North America (U.S., and Canada), Europe (U.K., Germany, France, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East amp; Africa (GCC, South Africa, and Rest of Middle East amp; Africa).

Key Takeaways:

What is the market size in 2018 and the growth rate of the Global Tuberculosis Drugs Market?

What is the market drivers, restrains, opportunities governing the Global Tuberculosis Drugs Market?

Which are the largest and the fastest growing segments in the Global Tuberculosis Drugs Market?

Who are the key players operating in the market and their market position?

What is the pipeline scenario, drug pricing analysis and technological development in the market?

View Detail Report With Complete Table Of Content@ http://www.amecoresearch.com/market-report/global-tuberculosis-drugs-market-emr-12314

Factor driving the market are increasing number of TB patients, rising awareness among people, and growing number of research and development activities in novel drug development. Moreover, technological advancement in early stage detection, and government and non government organizations initiatives to promote TB drugs are further augmenting the growth of the market. The years used for the assessment are as follows:

Historical year: 2014, 2015 and 2016

Base year: 2017

Forecast period: 2018 ndash; 2024

RESEARCH METHODOLOGY

The research and analysis is based on the data and information obtained from various primary and secondary sources. The data obtained is validated by interacting with the companies of the concerned domain. The steps involved in the research methodology are;
Obtaining historical data of the market based on news, articles, publications, annual reports, white papers, surveys, and other secondary sources
Interacting with key opinion leaders of the market and developing data points based on interaction with them
Study of past trends in the market and their year on year Impact on the market size and share
Analyzing the collected data points
Bridging the data points to calculate the total global tuberculosis drugs market and its various segments
Anticipating potential risks
Analyzing market forces such as drivers, restraints, and opportunities to assess new growth areas for the global tuberculosis drugs market
Finalizing the overall size and share of the global tuberculosis drugs market

OBJECTIVES:

To analyze market trends, opportunities, drivers, and restraints associated with the global tuberculosis drugs market
To study market response with respect to the mergers and acquisitions in the industry
To profile key companies operating in the global tuberculosis drugs market and provide their competitive landscape

MARKET SCOPE

The research scope for Global Tuberculosis Drugs Market is as follows:

By Type
Active Tuberculosis
Latent Tuberculosis

By Drugs Class
First-line anti-TB drugs
Isoniazid
Ethambutol
Pyrazinamide
Rifampicin
Rifabutin
Streptomycin
Others

Second-line anti-TB drugs
Cycloserine
Moxifloxacin
Gatifloxacin
Amikacin/Kanamycin
Ethionamide
Capreomycin
Others
Combination drugs

By Distribution Channel
Retail Pharmacy
Hospital Pharmacy
Others

By Region
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

FREE ANALYSIS

The global tuberculosis drugs market was estimated at USD 1,046 million in 2017 and is expected to reach USD 1,432 million in 2024 at a CAGR of 4.6% during the forecast period. Factor driving the market are increasing number of TB patients, rising awareness among people, and growing number of research and development activities in novel drug development. Moreover, technological advancement in early stage detection, and government amp; non government organization initiatives to promote TB drugs are further augmenting the growth of the market.

Tuberculosis (TB) is caused by the Mycobacterium tuberculosis bacteria and is highly contagious disease. TB is caused by inhaling tuberculosis bacilli in the air. According to the World Health Organization (WHO), in 2016, about 10.4 million people across the globe became infected with TB. In developing countries, tuberculosis remains a significant cause of both illness and death. The rise in TB drugs in developing countries is due to growing number of patients diagnosed with TB, as well as rising awareness among people about its treatment.

The U.S. Agency for International Development (USAID) support diagnosis and treatment services for millions of people which are affected by TB and multidrug resistance tuberculosis. Asia-Pacific holds the maximum share of the market, owing to growing number of TB patients in countries such as, Philippines, Nigeria, Indonesia, South Africa, Pakistan, and China.

Table Of Contents

Global Tuberculosis Drugs Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation amp; Forecast 2024

CHAPTER 1. Market Scope and Methodology

1.1. Research methodology

1.2. Research scope amp; assumptions

1.3. List of data sources

CHAPTER 2. Executive Summary

2.1. Tuberculosis Drugs ndash; Market Snapshot

CHAPTER 3. Industry Analysis

3.1. Market definition

3.2. Market segmentation

3.3. Key findings of the Global Tuberculosis Drugs Market

3.4. Value chain analysis

3.5. Market challenges

3.6. Market opportunities amp; trends

3.7. Market dynamics

3.7.1. Market driver analysis

3.7.1.1. Growing awareness among people

3.7.1.2. Government and non government organization to promote awareness of medicines

3.7.1.3. Growing development in diagnosis management

3.7.1.4. Increasing research and development activities

3.7.2. Market restraint analysis

3.7.2.1. Side effect of drugs

3.7.3. Industry Analysis-Porters five forces of analysis

CHAPTER 4. Competitive Outlook

4.1. Competitive analysis

4.2. Competitive factors

4.3. Strategies adopted

CHAPTER 5. Global Tuberculosis Drugs Market Size and Forecast (2014 ndash; 2024) (USD Million)

5.1. Global Tuberculosis Drugs Market, By Disease Type(USD Million)

5.1.1. Active Tuberculosis

5.1.2. Latent Tuberculosis

5.2. Global Tuberculosis Drugs Market, By Drugs Class(USD Million)

5.2.1. First-line anti-TB drugs

5.2.1.1. Isoniazid

5.2.1.2. Ethambutol

5.2.1.3. Pyrazinamide

5.2.1.4. Rifampicin

5.2.1.5. Rifabutin

5.2.1.6. Streptomycin

5.2.1.7. Others

5.2.2. Second-line anti-TB drugs(USD Million)

5.2.2.1. Cycloserine

5.2.2.2. Moxifloxacin

5.2.2.3. Gatifloxacin

5.2.2.4. Amikacin / Kanamycin

5.2.2.5. Ethionamide

5.2.2.6. Capreomycin

5.2.2.7. Others

5.2.3. Combination drugs

5.3. Global Tuberculosis Drugs Market, By Distribution Channel (USD Million)

5.3.1. Retail Pharmacy

5.3.2. Hospital Pharmacy

5.3.3. Others

CHAPTER 6. Global Tuberculosis Drugs Market Size and Forecast, By Geography (2014-2024) (USD Million)

6.1. North America Tuberculosis Drugs Market

6.1.1. North America Tuberculosis Drugs Market, By Type (USD Million)

6.1.2. North America Tuberculosis Drugs Market, By Drugs Class (USD Million)

6.1.3. North America Tuberculosis Drugs Market, By Distribution Channel (USD Million)

6.1.4. North America Tuberculosis Drugs Market, By Country

6.1.4.1. U.S.

6.1.4.2. Canada

6.2. Europe Tuberculosis Drugs Market

6.2.1. Europe Tuberculosis Drugs Market, By Type (USD Million)

6.2.2. Europe Tuberculosis Drugs Market, By Drugs Class (USD Million)

6.2.3. Europe Tuberculosis Drugs Market, By Distribution Channel (USD Million)

6.2.4. Europe Tuberculosis Drugs Market, By Country

6.2.4.1. Germany

6.2.4.2. France

6.2.4.3. U.K.

6.2.4.4. Italy

6.2.4.5. Spain

6.2.4.6. Rest of Europe

6.3. Asia-Pacific Tuberculosis Drugs Market

6.3.1. Asia-Pacific Tuberculosis Drugs Market, By Type (USD Million)

6.3.2. Asia-Pacific Tuberculosis Drugs Market, By Drugs Class (USD Million)

6.3.3. Asia-Pacific Tuberculosis Drugs Market, By Distribution Channel (USD Million)

6.3.4. Asia-Pacific Tuberculosis Drugs Market, By Country

6.3.4.1. China

6.3.4.2. Australia

6.3.4.3. Japan

6.3.4.4. India

6.3.4.5. Indonesia

6.3.4.6. Philippines

6.3.4.7. Rest of Asia-Pacific

6.4. Latin America Tuberculosis Drugs Market

6.4.1. Latin America Tuberculosis Drugs Market, By Type (USD Million)

6.4.2. Latin America Tuberculosis Drugs Market, By Drugs Class (USD Million)

6.4.3. Latin America Tuberculosis Drugs Market, By Distribution Channel (USD Million)

6.4.4. Latin America Tuberculosis Drugs Market, By Country

6.4.4.1. Mexico

6.4.4.2. Brazil

6.4.4.3. Rest of Latin America

6.5. Middle East and Africa Tuberculosis Drugs Market

6.5.1. Middle East and Africa Tuberculosis Drugs Market, By Type (USD Million)

6.5.2. Middle East and Africa Tuberculosis Drugs Market, By Drugs Class (USD Million)

6.5.3. Middle East and Africa Tuberculosis Drugs Market, By Distribution Channel (USD Million)

6.5.4. Middle East and Africa Tuberculosis Drugs Market, By Country

6.5.4.1. UAE

6.5.4.2. South Africa

6.5.4.3. Rest of Middle East and Africa

CHAPTER 7. Key Players and Strategic Developments

7.1. Bayer AG

7.1.1. Business Overview

7.1.2. Product and Service Offering

7.1.3. Financial Overview

7.1.4. Strategic Developments

7.2. Lupin Limited

7.2.1. Business Overview

7.2.2. Product and Service Offering

7.2.3. Financial Overview

7.2.4. Strategic Developments

7.3. GlaxoSmithKline plc.

7.3.1. Business Overview

7.3.2. Product and Service Offering

7.3.3. Financial Overview

7.3.4. Strategic Developments

7.4. Zydus Cadila

7.4.1. Business Overview

7.4.2. Product and Service Offering

7.4.3. Financial Overview

7.4.4. Strategic Developments

7.5. Pfizer, Inc.

7.5.1. Business Overview

7.5.2. Product and Service Offering

7.5.3. Financial Overview

7.5.4. Strategic Developments

7.6. Sanofi

7.6.1. Business Overview

7.6.2. Product and Service Offering

7.6.3. Financial Overview

7.6.4. Strategic Developments

7.7. Novartis AG

7.7.1. Business Overview

7.7.2. Product and Service Offering

7.7.3. Financial Overview

7.7.4. Strategic Developments

7.8. AstraZeneca

7.8.1. Business Overview

7.8.2. Product and Service Offering

7.8.3. Financial Overview

7.8.4. Strategic Developments

7.9. Merck amp; Co., Inc.

7.9.1. Business Overview

7.9.2. Product and Service Offering

7.9.3. Financial Overview

7.9.4. Strategic Developments

7.10. Sandoz International GmbH

7.10.1. Business Overview

7.10.2. Product and Service Offering

7.10.3. Financial Overview

7.10.4. Strategic Developments

7.11. Abbreviation

Quick Buy This Premium Report From Here: http://www.amecoresearch.com/buy/12314

About Us:

Ameco Research is the one spot destination for all your research needs. Ameco Research holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.

Contact:

Email: sales@amecoresearch.com | +1 407 915 4157

Editor Details

Last Updated: 25-Jun-2019